Nothing Special   »   [go: up one dir, main page]

Zhang et al., 2018 - Google Patents

Impact of dopamine oxidation on dopaminergic neurodegeneration

Zhang et al., 2018

Document ID
7166949327637550057
Author
Zhang S
Wang R
Wang G
Publication year
Publication venue
ACS chemical neuroscience

External Links

Snippet

Parkinson's disease (PD) is the second most common neurodegenerative disease. The characteristic feature of PD is the progressive degeneration of the dopaminergic (DAergic) neurons in the substantia nigra (SN). DAergic neurons in the SN accumulate black and …
Continue reading at pubs.acs.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Zhang et al. Impact of dopamine oxidation on dopaminergic neurodegeneration
Herrera et al. Are dopamine oxidation metabolites involved in the loss of dopaminergic neurons in the nigrostriatal system in Parkinson’s disease?
Puspita et al. Oxidative stress and cellular pathologies in Parkinson’s disease
Li et al. PARK genes link mitochondrial dysfunction and alpha-synuclein pathology in sporadic Parkinson’s disease
Post et al. Can interactions between α-synuclein, dopamine and calcium explain selective neurodegeneration in Parkinson's disease?
Unzeta et al. Multi-target directed donepezil-like ligands for Alzheimer's disease
Llanos-González et al. Interplay between mitochondrial oxidative disorders and proteostasis in Alzheimer’s disease
Munoz-Soriano et al. Drosophila models of Parkinson′ s disease: discovering relevant pathways and novel therapeutic strategies
Walker et al. Stress signaling from the endoplasmic reticulum: A central player in the pathogenesis of amyotrophic lateral sclerosis
S Hernandes et al. NADPH oxidase and neurodegeneration
Perez et al. Could a loss of α‐synuclein function put dopaminergic neurons at risk?
Avramovich‐Tirosh et al. Therapeutic targets and potential of the novel brain‐permeable multifunctional iron chelator–monoamine oxidase inhibitor drug, M‐30, for the treatment of Alzheimer's disease 1
Xilouri et al. Alpha-synuclein and protein degradation systems: a reciprocal relationship
Ma et al. Amyloid β-induced impairments in hippocampal synaptic plasticity are rescued by decreasing mitochondrial superoxide
Biosa et al. Dopamine oxidation products as mitochondrial endotoxins, a potential molecular mechanism for preferential neurodegeneration in Parkinson’s disease
Galindo et al. Mitochondrial biology in Alzheimer’s disease pathogenesis
Schubert et al. The induction of HIF‐1 reduces astrocyte activation by amyloid beta peptide
Bose et al. Mitochondrial dysfunction and oxidative stress in induced pluripotent stem cell models of Parkinson's disease
Bandopadhyay et al. Pathogenesis of Parkinson's disease: emerging role of molecular chaperones
Li et al. Mitochondrial function and Parkinson’s disease: from the perspective of the electron transport chain
Segura-Aguilar et al. Mechanisms of dopamine oxidation and Parkinson’s disease
Fuentes et al. Inhibition of VMAT-2 and DT-diaphorase induce cell death in a substantia nigra-derived cell line an experimental cell model for dopamine toxicity studies
Huenchuguala et al. The importance of mitophagy in maintaining mitochondrial function in U373MG cells. Bafilomycin A1 restores aminochrome-induced mitochondrial damage
Rane et al. Novel targets for Parkinson’s disease: addressing different therapeutic paradigms and conundrums
Kaminsky et al. Effects of amyloid-beta peptides on hydrogen peroxide-metabolizing enzymes in rat brain in vivo